ClinicaliQ Trial Snapshot
- Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) — Active Not Recruiting • Phase III • Oncology • NCT04662255.
- Pirtobrutinib versus standard BTK inhibitors for mantle cell lymphoma treatment comparison.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This is a study for participants with a type of blood cancer called mantle cell lymphoma (MCL). The main purpose is to compare pirtobrutinib (LOXO-305) to other drugs that work in a similar way that have already been approved by the United States Food and Drug Administration (US FDA). Participation could last up to two years, and possibly longer, if the disease does not progress. Conditions: Lymphoma, Mantle-Cell Interventions: Pirtobrutinib, Ibrutinib, Acalabrutinib, Zanubrutinib Lead Sponsor: Loxo Oncology, Inc. Planned Enrollment: 500 participants